Israel Englander Vincerx Pharma, Inc. Transaction History

Millennium Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.57 - $6.6 $8,264 - $95,693	-14,499 Reduced 55.89%	11,445 $9,000
Q1 2024 May 15, 2024	SELL	$1.07 - $8.06 $9,120 - $68,703	-8,524 Reduced 24.73%	25,944 $131,000
Q4 2023 Feb 14, 2024	SELL	$0.62 - $1.18 $15,232 - $28,990	-24,568 Reduced 41.62%	34,468 $40,000
Q2 2023 Aug 14, 2023	SELL	$0.88 - $1.9 $23,002 - $49,664	-26,139 Reduced 30.69%	59,036 $76,000
Q1 2023 May 15, 2023	BUY	$0.9 - $1.51 $13,589 - $22,799	15,099 Added 21.55%	85,175 $89,000
Q4 2022 Feb 14, 2023	SELL	$0.64 - $1.32 $88,023 - $181,547	-137,536 Reduced 66.25%	70,076 $71,000
Q3 2022 Nov 14, 2022	SELL	$0.0 - $1.72 $0 - $170,255	-98,986 Reduced 32.29%	207,612 $287,000

11M

Ticker VINC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,189,800
Market Cap $4.03M
Description
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candid...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.